TransDerm Inks Research Deal with RXi, Gets Grant to Explore Delivery Technologies

In addition to evaluating RXi's proprietary RNAi compounds, TransDerm will test delivery technologies from Traversa Therapeutics, Thermo Fisher Scientific, and Life Technologies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.